iNtRON Biotechnology Inc
iNtRON Biotechnology, Inc. engages in the development of novel drugs in South Korea. It develops bacteriophage and endolysin based drugs. The company was founded in 1999 and is headquartered in Seongnam-si, South Korea.
iNtRON Biotechnology Inc (048530) - Net Assets
Latest net assets as of September 2025: ₩73.98 Billion KRW
Based on the latest financial reports, iNtRON Biotechnology Inc (048530) has net assets worth ₩73.98 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩78.70 Billion) and total liabilities (₩4.73 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩73.98 Billion |
| % of Total Assets | 93.99% |
| Annual Growth Rate | 17.64% |
| 5-Year Change | -1.88% |
| 10-Year Change | 143.23% |
| Growth Volatility | 59.56 |
iNtRON Biotechnology Inc - Net Assets Trend (2012–2024)
This chart illustrates how iNtRON Biotechnology Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for iNtRON Biotechnology Inc (2012–2024)
The table below shows the annual net assets of iNtRON Biotechnology Inc from 2012 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩83.77 Billion | -13.40% |
| 2023-12-31 | ₩96.73 Billion | -8.90% |
| 2022-12-31 | ₩106.18 Billion | +4.77% |
| 2021-12-31 | ₩101.35 Billion | +18.71% |
| 2020-12-31 | ₩85.38 Billion | +31.43% |
| 2019-12-31 | ₩64.96 Billion | +66.18% |
| 2018-12-31 | ₩39.09 Billion | +29.25% |
| 2017-12-31 | ₩30.24 Billion | -38.46% |
| 2016-12-31 | ₩49.15 Billion | +42.71% |
| 2015-12-31 | ₩34.44 Billion | +188.72% |
| 2012-12-31 | ₩11.93 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to iNtRON Biotechnology Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 24496.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩42.77 Billion | 51.05% |
| Other Components | ₩41.00 Billion | 48.95% |
| Total Equity | ₩83.77 Billion | 100.00% |
iNtRON Biotechnology Inc Competitors by Market Cap
The table below lists competitors of iNtRON Biotechnology Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Arcelik AS
IS:ARCLK
|
$83.99 Million |
|
Simplex Infrastructures Limited
NSE:SIMPLEXINF
|
$84.00 Million |
|
Semperit AG Holding
LSE:0G29
|
$84.04 Million |
|
Charlton Aria Acquisition Corporation Units
NASDAQ:CHARU
|
$84.04 Million |
|
eToro Group Ltd.
NASDAQ:ETOR
|
$83.96 Million |
|
SELECTQUOTE INC. DL -01
F:6SJA
|
$83.95 Million |
|
Third Harmonic Bio Inc.
NASDAQ:THRD
|
$83.95 Million |
|
Webjet Group Ltd
AU:WJL
|
$83.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in iNtRON Biotechnology Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 96,734,229,010 to 83,772,673,340, a change of -12,961,555,670 (-13.4%).
- Net loss of 2,591,158,400 reduced equity.
- Dividend payments of 3,319,154,700 reduced retained earnings.
- Share repurchases of 7,186,050,720 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-2.59 Billion | -3.09% |
| Dividends Paid | ₩3.32 Billion | -3.96% |
| Share Repurchases | ₩7.19 Billion | -8.58% |
| Other Changes | ₩134.81 Million | +0.16% |
| Total Change | ₩- | -13.40% |
Book Value vs Market Value Analysis
This analysis compares iNtRON Biotechnology Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.79x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.86x to 1.79x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1641.36 | ₩4690.00 | x |
| 2017-12-31 | ₩1010.03 | ₩4690.00 | x |
| 2018-12-31 | ₩1305.49 | ₩4690.00 | x |
| 2019-12-31 | ₩2169.46 | ₩4690.00 | x |
| 2020-12-31 | ₩2598.51 | ₩4690.00 | x |
| 2021-12-31 | ₩3004.79 | ₩4690.00 | x |
| 2022-12-31 | ₩3199.04 | ₩4690.00 | x |
| 2023-12-31 | ₩2914.42 | ₩4690.00 | x |
| 2024-12-31 | ₩2619.70 | ₩4690.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently iNtRON Biotechnology Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -40.37%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 1.03x
- Recent ROE (-3.09%) is below the historical average (0.11%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -9.93% | -14.49% | 0.42x | 1.65x | ₩-2.38 Billion |
| 2015 | 4.52% | 13.16% | 0.29x | 1.17x | ₩-1.89 Billion |
| 2016 | -1.24% | -5.97% | 0.17x | 1.21x | ₩-5.53 Billion |
| 2017 | -28.88% | -79.67% | 0.24x | 1.51x | ₩-11.76 Billion |
| 2018 | 22.28% | 42.32% | 0.38x | 1.40x | ₩4.80 Billion |
| 2019 | -4.91% | -38.18% | 0.09x | 1.37x | ₩-9.68 Billion |
| 2020 | 17.51% | 32.90% | 0.45x | 1.18x | ₩6.41 Billion |
| 2021 | 9.60% | 33.19% | 0.19x | 1.51x | ₩-406.89 Million |
| 2022 | 5.38% | 40.78% | 0.10x | 1.33x | ₩-4.91 Billion |
| 2023 | -10.02% | -101.15% | 0.10x | 1.02x | ₩-19.37 Billion |
| 2024 | -3.09% | -40.37% | 0.07x | 1.03x | ₩-10.97 Billion |
Industry Comparison
This section compares iNtRON Biotechnology Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $225,770,608,637
- Average return on equity (ROE) among peers: -11.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| iNtRON Biotechnology Inc (048530) | ₩73.98 Billion | -9.93% | 0.06x | $83.99 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |